'On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Torrent Pharmaceuticals has increased 14.30% to Rs 3302 crore. Operating profit margin has jumped from 32.50% to 32.80%, leading to 15.34% rise in operating profit to Rs 1,083.00 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 11.50% to 11.70%. Purchase of finished goods cost fell from 13.04% to 11.70%. Employee cost increased from 18.53% to 19.20%. Other expenses fell from 24.88% to 24.25%.
Other income fell 68.75% to Rs -27 crore. PBIDT rose 14.41% to Rs 1056 crore. Provision for interest fell 25% to Rs 48 crore. Loan funds declined from Rs 3,128.00 crore as of 30 September 2024 to Rs 2,822.00 crore as of 30 September 2025. Sundry debtors were higher at Rs ...
Pleaselogin & subscribe to view the full report.
More Reports
|
|